V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016291 | 160013270 | 1.25 | 68 | Curative (C) | 2018-01-29 | 2018-01-29 | null | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 100344862 |
| 160016298 | 160013271 | 1.62 | null | Neo-adjuvant (N) | 2016-05-07 | 2016-07-05 | Ifosfamide | 02 | null | TRIAL | 100029791 |
| 160016299 | 160013272 | 1.68 | 46.2 | Neo-adjuvant (N) | 2019-10-30 | 2020-06-25 | NB Rel CCLG guidelines Cyclo-Topotecan | 02 | N | CYCLOPHOSPHAMIDE + TOPOTECAN | 101510050 |
| 160016301 | 160013273 | 0 | 114.6 | Adjuvant (A) | 2016-09-19 | 2016-09-25 | Abiraterone | 02 | N | VIA | 100811274 |
| 160016302 | 160013274 | 0 | 116 | Curative (C) | 2018-02-01 | 2018-05-10 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | null | OLARATUMAB | 100401926 |
| 160016304 | 160013275 | 1.65 | 68.8 | null | 2017-09-05 | 2018-04-28 | IVADo | 02 | null | OLARATUMAB | 100017071 |
| 160016307 | 160013276 | 0 | 50.35 | Curative (C) | 2017-09-16 | 2017-09-16 | CARBOPLATIN + ETOPOSIDE | 02 | N | DINUTUXIMAB BETA | 100095618 |
| 160016308 | 160013277 | 1.79 | 38 | Palliative (P) | 2018-11-18 | 2019-05-12 | Cabazitaxel | N | N | AZACITIDINE | 101681747 |
| 160016309 | 160013278 | 1.56 | 67.8 | null | 2017-02-07 | 2017-03-14 | Olaparib | 02 | null | AXITINIB | 100318550 |
| 160016314 | 160013279 | 1.73 | 92.9 | Curative (C) | 2016-06-26 | 2016-06-27 | Pemetrexed | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100726127 |
| 160016316 | 160013280 | 1.82 | 19.4 | null | 2017-06-11 | 2017-06-11 | Cyclophosphamide High Dose | N | null | IFOSFAMIDE | 100605956 |
| 160016320 | 160013281 | 1.59 | 46 | 03 | 2013-10-25 | 2016-07-05 | Cyclophosphamide oral | 02 | N | PROMISE-MESO TRIAL | 101769475 |
| 160016323 | 160013282 | 1.83 | 114.6 | Palliative (P) | 2018-09-01 | 2018-10-11 | Bevacizumab+Carbo+Pacliaxel | 01 | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 101402071 |
| 160016340 | 160013284 | 1.64 | 67.6 | Curative (C) | 2020-04-12 | 2020-04-15 | Olaratumab | 02 | N | IVA | 100530002 |
| 160016341 | 160013285 | null | 104 | Palliative (P) | 2021-04-05 | 2021-05-02 | Methotrexate High Dose (3g/m2) | 02 | N | LAROTRECTINIB | 101869418 |
| 160016342 | 160013286 | 1.6 | 52.9 | Curative (C) | 2019-08-16 | 2019-08-17 | GEMCITABINE | 2 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100428007 |
| 160016345 | 160013287 | 1.46 | 38.6 | Curative (C) | 2019-06-23 | 2019-06-29 | IPILIMUMAB + NIVOLUMAB | 02 | null | VINCRISTINE | 100784492 |
| 160016347 | 160013288 | 1.77 | 107.2 | null | 2016-10-04 | 2016-10-04 | Cyclophosphamide + Topotecan | 02 | null | DOXORUBICIN + IFOSFAMIDE | 101595710 |
| 160016348 | 160013289 | 1.83 | 14.9 | Curative (C) | 2018-01-12 | 2018-01-13 | NB HRNBL-1 BUMEL MAT | 01 | N | STS NON-RHABDO EPSSG 2005 IFOS | 100954658 |
| 160016350 | 160013290 | 1.68 | 84.6 | null | 2016-09-14 | 2016-09-19 | EW EuroEwing 2012 Arm B IE | 02 | null | ATOMIC-MESO TRIAL | 100598980 |
| 160016356 | 160013291 | 1.82 | 95.7 | 03 | 2017-01-11 | 2017-09-27 | GEMCITABINE | 02 | N | CNS MEDBL HR THIOTEPA | 100530545 |
| 160016361 | 160013293 | 1.7 | 71 | Palliative (P) | 2020-02-23 | 2020-02-23 | GEMCITABINE | 02 | N | PEMBROLIZUMAB | 101091128 |
| 160016362 | 160013294 | 0 | 73.8 | null | 2018-06-13 | 2018-07-02 | VINCRISTINE | null | null | EW EUROEWING 2012 ARM B VDC/IE | 101279426 |
| 160016365 | 160013295 | 1.72 | 35.1 | 03 | 2017-10-23 | 2017-10-24 | null | 02 | N | GEMCITABINE | 100701065 |
| 160016366 | 160013296 | 0 | 53.8 | null | 2017-06-20 | 2017-06-24 | PEMBROLIZUMAB | 02 | null | STS RHABDO VIT0910 VINC IRINO TEMOZ | 101311932 |
| 160016368 | 160013297 | 0 | 16.7 | Palliative (P) | 2017-11-27 | 2017-12-02 | Cytarabine intrathecal | 02 | N | GC INT GUIDE EXCRANIAL GERMCELL JEB | 101578769 |
| 160016371 | 160013298 | 1.62 | 118.6 | null | 2018-01-07 | 2018-04-15 | IVA | 02 | N | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 101092422 |
| 160016372 | 160013299 | 1.71 | 85.1 | Palliative (P) | 2016-11-19 | 2016-12-10 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 2 | N | CYCLOPHOSPHAMIDE | 100418692 |
| 160016374 | 160013300 | 1.67 | 62.3 | null | 2018-11-19 | 2019-01-03 | NB HRNBL-1 Isotretinoin | 02 | null | IPM | 101130449 |
| 160016388 | 160013301 | 0 | 56.3 | Palliative (P) | 2017-06-30 | 2017-12-06 | Niraparib | 02 | null | IFOSFAMIDE | 101042391 |
| 160016389 | 160013302 | 1.64 | 98.5 | null | 2016-07-12 | 2016-09-04 | GemCarbo Days 1+8 | 99 | null | NB HRNBL | 100501408 |
| 160016392 | 160013303 | 1.55 | 86 | Palliative (P) | 2019-08-17 | 2019-08-21 | EW EuroEwing 2012 Arm B IE | 02 | null | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 101645454 |
| 160016397 | 160013304 | 1.24 | 39.1 | null | 2019-08-16 | 2019-09-14 | Ifosfamide | 02 | null | CYCLOPHOSPHAMIDE + VINORELBINE | 100996157 |
| 160016399 | 160013305 | 0 | 109.4 | Palliative (P) | 2018-03-20 | 2018-05-26 | Gem-Dex | N | N | STS RHABDO RMS 2005 VIN CYCLO | 100864276 |
| 160016402 | 160013306 | 1.72 | 70.6 | null | 2019-07-18 | 2019-09-05 | EW EuroEwing 2012 Arm B VC | 02 | null | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 100789613 |
| 160016403 | 160013307 | 1.68 | 55.1 | Curative (C) | 2016-06-16 | 2016-09-20 | TAZEMETOSTAT | 02 | N | RITUXIMAB | 100364118 |
| 160016409 | 160013309 | 1.56 | 43.5 | Palliative (P) | 2018-12-11 | 2018-12-19 | PROMISE-MESO TRIAL | 02 | N | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 101579720 |
| 160016412 | 160013310 | 1.64 | 93.9 | null | 2019-04-14 | 2021-04-10 | GemCarbo Days 1+8 | 02 | null | DOXORUBICIN + IFOSFAMIDE | 101739440 |
| 160016414 | 160013311 | 1.53 | 56.3 | Curative (C) | 2018-10-14 | 2018-10-17 | ATEZOLIZUMAB + NAB PACLITAXEL | 02 | N | GEMCITABINE | 100970816 |
| 160016418 | 160013312 | 1.72 | 61.5 | null | 2016-04-22 | 2016-04-25 | Docetaxel | N | null | STS RHABDO RMS 2005 VIN CYCLO | 100563166 |
| 160016420 | 160013313 | 0 | 11.6 | Palliative (P) | 2019-06-23 | 2019-07-20 | Lenalidomide 25mg (Cycle 1 to 25) | 02 | N | CARBOPLATIN + VINORELBINE | 101362526 |
| 160016421 | 160013314 | null | 72.5 | null | 2016-09-29 | 2018-12-21 | Cyclophosphamide oral | 02 | null | METHOTREXATE | 100279655 |
| 160016426 | 160013316 | 1.88 | 75.1 | Curative (C) | 2018-10-23 | 2018-10-29 | Olaparib | 02 | N | DACARBAZINE + GEMCITABINE | 100229089 |
| 160016428 | 160013317 | 1.65 | 79.2 | null | 2018-10-15 | 2019-12-27 | EW EuroEwing 2012 Arm A VAC | 01 | null | CYCLOPHOSPHAMIDE + VINORELBINE | 101731054 |
| 160016429 | 160013318 | 1.67 | 119.3 | null | 2017-04-11 | 2017-05-13 | VINCRISTINE | N | null | NOT MATCHED | 100736808 |
| 160016430 | 160013319 | 0 | 51.4 | null | 2020-09-18 | 2020-09-23 | Pazopanib | 02 | null | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 101052599 |
| 160016432 | 160013320 | 1.64 | 81.5 | null | 2018-01-05 | 2018-01-26 | Rucaparib | 01 | null | ETOPOSIDE | 101507553 |
| 160016438 | 160013321 | 0 | 59.8 | null | 2017-07-21 | 2017-10-27 | Ifosfamide | null | null | NOT MATCHED | 101055507 |
| 160016440 | 160013322 | 1.82 | 75.7 | Palliative (P) | 2016-07-14 | 2016-12-11 | Doxorubicin + Ifosfamide | 02 | N | GEMCITABINE | 100907107 |
| 160016442 | 160013323 | 0 | 86.8 | null | 2019-04-22 | 2019-09-30 | Cyclophosphamide Weekly PO | 01 | null | IFOSFAMIDE | 101327979 |